|
|
(גרסת ביניים אחת של אותו משתמש אינה מוצגת) |
שורה 1: |
שורה 1: |
− | {{תרופה
| + | #הפניה [[t:Pravastatin]] |
− | |שמות נוספים=
| |
− | |שמות מסחריים= ®PRAVALIP® ; PRAVASTATIN
| |
− | |תמונה=
| |
− | |כיתוב תמונה=
| |
− | |קבוצה פרמקולוגית (ATC)=[http://www.old.health.gov.il/units/pharmacy/trufot/Mucar_List.asp?p=1&Sr_Type=ATC&Y_Name=C10AA&Letter=C10AA&safa=h "HMG COA REDUCTASE INHIBITORS"]
| |
− | |קישור למאגר משרד הבריאות=[http://www.old.health.gov.il/units/pharmacy/trufot/Mucar_List.asp?p=1&Sr_Type=Activ&Y_Name=PRAVASTATIN&Letter=Pravastatin&safa=h "פראבאסטאטין"]
| |
− | |סל הבריאות=כלול
| |
− | |מסגרת הכללה בסל=תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
| |
− | |התוויות= Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute coronary events. Myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels Pravastatin is indicated to: - Reduce the risk of recurrent myocardial infarction. - Reduce the risk of undergoing myocardial revascularization procedures. - Reduce the risk of stroke and transient ischemic attack (TIA). *Hypercholesterolemia and mixed dyslipidemia: Pravastatin is indicated as an adjunct to diet to reduce elevated Total-C LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb)
| |
− | |קיים גם בתכשירים=
| |
− | |שם יצרן=
| |
− | |שם בעל הרישום=
| |
− | |עלון לרופא=
| |
− | |עלון לצרכן=
| |
− | |מינונים=
| |
− | }}
| |
− | {{הרחבה|סטטין}}
| |
− | [[קטגוריה: מאגר תרופות]]
| |